BioNexus Gene Lab Corp. Cost of Goods Sold, Sales-type Lease
BioNexus Gene Lab Corp. (BGLC) reported Cost of Goods Sold, Sales-type Lease of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSoldSalesTypeLease · last filed 2026-08-14
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for the quarter ending 2025-12-31 was $10.47K, a 77.80% decline year-over-year.
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for the quarter ending 2025-09-30 was $25.65K, a 9.35% increase year-over-year.
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for fiscal 2025 was $68.10K, a 39.49% decline from fiscal 2024.
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for fiscal 2024 was $112.56K, a 5.27% increase from fiscal 2023.
- BioNexus Gene Lab Corp. cost of goods sold, sales-type lease for fiscal 2023 was $106.92K.
| Period end | Cost of Goods Sold, Sales-type Lease 3 month | Cost of Goods Sold, Sales-type Lease 6 month | Cost of Goods Sold, Sales-type Lease 9 month | Cost of Goods Sold, Sales-type Lease 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $10.47K derived: sum of 3 quarters · filed 2026-08-14 | $36.12K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $10.47K derived: sum of 2 quarters · filed 2026-05-15 | $36.12K derived: sum of 3 quarters · filed 2026-05-15 | $52.23K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $10.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $36.12K derived: sum of 2 quarters · filed 2026-04-14 | $52.23K derived: sum of 3 quarters · filed 2026-08-14 | $68.10K 10-K · filed 2026-04-14 |
| 2025-09-30 | $25.65K 10-Q · filed 2025-11-14 | $41.76K derived: sum of 2 quarters · filed 2026-08-14 | $57.63K 10-Q · filed 2025-11-14 | $105.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $16.11K 10-Q · filed 2026-08-14 | $32.18K 10-Q · filed 2026-08-14 | $79.36K derived: sum of 3 quarters · filed 2026-08-14 | $102.81K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $16.07K 10-Q · filed 2026-05-15 | $63.25K derived: sum of 2 quarters · filed 2026-05-15 | $86.70K derived: sum of 3 quarters · filed 2026-05-15 | $94.44K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $47.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-14 | $70.63K derived: sum of 2 quarters · filed 2026-04-14 | $78.37K derived: sum of 3 quarters · filed 2026-04-14 | $112.56K 10-K · filed 2026-04-14 |
| 2024-09-30 | $23.46K 10-Q · filed 2025-11-14 | $31.19K derived: sum of 2 quarters · filed 2025-11-14 | $65.38K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $7.74K 10-Q · filed 2025-08-18 | $41.82K 10-Q · filed 2025-08-18 | ||
| 2024-03-31 | $34.09K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $106.92K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |